Frustrated by the shortcomings of other health screenings, Tomorrow was founded by a team of cardiovascular surgeons and scientists to provide specialist screening that would have a measurable, long-term impact on people’s lives.
Say hello to Tomorrow
We started Tomorrow with the belief that we could create a health screening that would make a real difference to people’s long-term health.
The health of our cardiovascular system is fundamental to our overall health and wellbeing, but sadly this isn’t widely understood. Cardiovascular disease, which includes heart attack and stroke, is the leading cause of death worldwide and causes more than 25% of all deaths in the UK. If poor cardiovascular health was tackled, this would save more lives than beating any other single disease.
So we set about designing and developing a new type of screening, one based on robust, clinically proven science that puts cardiovascular health at its core. If every one of us looked after our cardiovascular health, we could all live longer, healthier and happier lives.
Together, we have over 60 years of experience working at the forefront of cardiovascular and clinical research. Our clinical work focuses on continually improving the world’s understanding, diagnosis and treatment of cardiovascular disease. And we are global leaders when it comes to using 3D tomographic ultrasound to image veins and arteries – this allows us to detect and measure the earliest stage of disease in a way that has never been accessible to the general population before.
Making a difference
We believe everyone can improve their cardiovascular health. So, we go beyond simple disease detection, to provide support and guidance that will have long term, transformational impact on our customers’ lives. Our advice is evidence-based, actionable and practical. And we cut through the sheer volume of often contradictory health information out there by helping our customers prioritise what they can do to safeguard their future health.
State-of-the-art screening facility
We’ve partnered with the team at the Manchester Institute of Health & Performance (MIHP), a pioneering medicine and sports science to exclusively provide our Manchester screenings. Usually reserved for elite athletes and professional sports teams, our screenings take place in their modern and comfortable facility..
Meet the founders
Prof Charles McCollum, MBChB, FRCS, MD
Professor McCollum is one of the UK's leading cardiovascular experts. He was appointed Professor of Surgery and Head of the Department of Surgery at the University of Manchester in 1989 and is an Honorary Consultant Surgeon at South Manchester University Hospital. He runs a tertiary referral practice in carotid artery disease, cerebral perfusion, complex aneuryms and venous disease. Leading a research team of lecturers, fellows, scientists and technicians, his collaborations are with various disciplines including epidemiology, neuro-imaging, dementia services, stroke medicine, cardiology, mathematics, engineering and industry. He has published over 450 papers including 350 on original research.
Richard Pole, BSc(Hons), PGC, AVS
Richard has worked in vascular science for over 20 years. He is Operations Director for Independent Vascular Studies (IVS), the largest and most innovative vascular diagnostic and screening company in the UK. He leads a team of over fifty clinical vascular scientists, performing over 80,000 vascular investigations annually. He was awarded the Circulation Foundation prize in 2007 and the Anne Donald Vascular Scientist of the year award in 2015.
Adam Haque, MBChB, MRCS, PGCert.
Adam is a vascular surgeon in the North West. He has a special interest in exercise and fitness technologies for vascular patients, and is leading two research trials which have the potential to revolutionise lifestyle interventions in this patient group. He has specific expertise in how fitness influences cardiovascular risk and has become accomplished in cardiopulmonary exercise testing, recognising its potential as a key adjunct to improving health for our general population as a whole.